| 1 |
Werlenius K, Stragliotto G, Strandeus M, Blomstrand M, Carén H, Jakola AS, Rydenhag B, Dyregaard D, Dzhandzhugazyan KN, Kirkin AF, Raida MK, Smits A, Kinhult S. A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma. Neurooncol Adv 2021;3:vdab156. [PMID: 34765977 DOI: 10.1093/noajnl/vdab156] [Reference Citation Analysis]
|
| 2 |
Ait Ssi S, Chraa D, El Azhary K, Sahraoui S, Olive D, Badou A. Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades. Front Immunol 2021;12:685213. [PMID: 34539626 DOI: 10.3389/fimmu.2021.685213] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 3 |
Haddad AF, Young JS, Amara D, Berger MS, Raleigh DR, Aghi MK, Butowski NA. Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. Neurooncol Adv 2021;3:vdab100. [PMID: 34466804 DOI: 10.1093/noajnl/vdab100] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 4 |
Jia J, Ouyang Z, Wang M, Ma W, Liu M, Zhang M, Yu M. MicroRNA-361-5p slows down gliomas development through regulating UBR5 to elevate ATMIN protein expression. Cell Death Dis 2021;12:746. [PMID: 34321465 DOI: 10.1038/s41419-021-04010-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Sulman EP, Eisenstat DD. World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology. Front Oncol 2021;11:659800. [PMID: 34041027 DOI: 10.3389/fonc.2021.659800] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 6 |
Chawla S, Shehu V, Gupta PK, Nath K, Poptani H. Physiological Imaging Methods for Evaluating Response to Immunotherapies in Glioblastomas. Int J Mol Sci 2021;22:3867. [PMID: 33918043 DOI: 10.3390/ijms22083867] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 7 |
Haddad AF, Young JS, Aghi MK. Using viral vectors to deliver local immunotherapy to glioblastoma. Neurosurg Focus 2021;50:E4. [PMID: 33524947 DOI: 10.3171/2020.11.FOCUS20859] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 8 |
Haddad AF, Young JS, Mummaneni NV, Kasahara N, Aghi MK. Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies. J Neurooncol 2021;152:1-13. [PMID: 33389564 DOI: 10.1007/s11060-020-03684-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
